LRG1 and early-onset autosomal dominant Alzheimer disease: In line with this, while administration of selenomethionine, a well-known anti-oxidant compound, was reported to downregulate Lrg1 in a mouse model of Alzheimer’s disease [210], transgenic mice overexpressing LRG1 in neurons and glial cells showed significant brain atrophy [206], corroborating the hypothesis that LRG1 contributes to brain inflammation and cognitive impairment.